See Beyond the Expected.
Our team’s mission and vision for earlier detection of Leptomeningeal Metastases
At CNSide® Diagnostics, LLC, our company’s Mission is to revolutionize the clinical management of patients with Leptomeningeal Metastases (LM) through innovative diagnostic solutions.
Our company’s Vision is to improve patient outcomes by delivering cutting-edge diagnostics that enable personalized and effective treatment strategies.
Leadership Team
Russell Bradley
President & General Manager
Marc Hedrick, MD, MBA
President & CEO, Plus Therapeutics
Russ Havranek, MS, MBA
EVP, Commercial & Corporate Strategy
Jonathan Stein, PhD, HCLD(ABB)
Laboratory Director
Andrew Brenner, MD, PhD
Ad-Interim CMO
Andrew Sims, CPA
CFO & VP of Finance
Colby Suire, PhD
VP, Research and Development
Consolidated Clinical Laboratory & Manufacturing Facility in Houston, Texas
Full vertical integration in single facility
- Centrally located in the U.S. for efficient shipping and logistics
- Includes on-site advanced imaging, molecular analysis, cell-handling
- In-house manufacturing of key test components with ability to scale:
- CEE-Sure® CSF collection tube preservative
- Antibody mix
- Microfluidic chip
- Licensed with the Clinical Laboratory Improvement Amendments (CLIA) from the Centers for Medicare and Medicaid Services (CMS): CLIA Certificate of Accreditation 45D2308861
- Accreditation from the College of American Pathologists (CAP)
- Lab Director: Jonathan Stein, PhD, HCLD (ABB)
Our History
The CNSide® Cerebrospinal Fluid (CSF) Assay Platform was originally developed as a more sensitive and informative method for detecting and analyzing cancer cells in CSF compared to traditional CSF cytology.
CNSide® was initially launched in the U.S. by another company as a commercial assay in 2020. In 2022 and 2023, Plus Therapeutics partnered with and licensed the CNSide® technology from that company to support its own ReSPECT-LM clinical trials and development of the REYOBIQ targeted radiotherapeutic drug candidate for Leptomeningeal Metastases (LM). Plus Therapeutics acquired all CNSide® assets and established a new subsidiary, CNSide® Diagnostics, LLC, in 2024. The company is now focused on commercializing the CNSide® CSF Assay Platform in the U.S., starting with the Tumor Cell Enumeration (TCE) test.
Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
September 8, 2023Plus Therapeutics Announces Validation & Clinical Implementation of Leptomeningeal Cancer Cell Diagnostic
March 25, 2024Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
May 9, 2024Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 21, 2024Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
September 18, 2025CNSide Expands Licensing to 49 U.S. States
December 11, 2025Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test
April 7, 2026Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
May 7, 2026Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 4, 2026Careers
There are no open positions at this time.